A comprehensive review of preclinical BPC-157 research including its studied mechanisms, molecular structure, and key findings from published literature.
Written by the Peptide Labs Research Team
Published BPC-157 research is mostly preclinical, drawn from in-vitro work and animal models, chiefly rodents. Human clinical data is limited, the mechanism is still incompletely characterised, and much of the literature comes from a relatively concentrated set of research groups.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide of 15 amino acids, a partial sequence derived from the gastric protein BPC. It is a synthesised research compound and does not occur naturally in isolation.
| Property | Detail |
|---|---|
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| CAS | 137525-51-0 |
| Molecular weight | 1419.53 Da |
The sequence is rich in proline and glycine. Proline restricts rotation and introduces kinks, while glycine has no side chain and allows tight turns. Investigators have used truncated and substituted analogues to map observed activity to specific segments, rather than treating the full 15-mer as one unit.
Our BPC-157 10mg is independently verified at 99.2% HPLC purity, with full COA documentation including mass spectrometry identity confirmation.
Preclinical work has examined angiogenesis-related signalling, including VEGFR2 and FAK-paxillin pathways, and endothelial cell migration in vitro. Early work centred on the gastrointestinal tract, consistent with the compound's derivation from a gastric protein sequence. Rodent studies have also used musculoskeletal and central nervous system models.
A large share of these studies come from a few research groups, so the independence of the evidence base needs weighing in any assessment.
Peptide Labs supplies BPC-157 for in-vitro laboratory and research use only. This article summarises published preclinical literature for educational purposes. It is not medical advice, and all research must follow applicable ethical and regulatory standards.
VRX-0075 is a preclinical quintuple agonist reported to reduce body weight more than retatrutide in rats. What the ADA 2026 abstract shows and does not.
ResearchBrenipatide (LY3537031) is Lilly's investigational GIP/GLP-1 agonist, in phase 3 for alcohol use disorder and depression. Registered trials and unknowns.
99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne
Shop All Peptides